ABCC2 and acute lymphoblastic leukemia: Thus, the ABCC2 −24C>T polymorphism could be used to predict MTX toxicities and guide individualized treatment for childhood ALL, since prediction of MTX toxicities is a key issue in individualization of MTX treatment [6].